APL-1, an altered peptide ligand derived from heat-shock protein, alone or combined with methotrexate attenuates murine collagen-induced arthritis

Clinical and Experimental Medicine

Volumn 17, Issue 2, 2017, Pages 209-216

  Lorenzo, Norailys ^a   Altruda, Fiorella ^b   Silengo, Lorenzo ^b   del Carmen Dominguez, Maria ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b Molecular Biotechnology Center   (Italy)

Author keywords

APL; Collagen induced arthritis; HSP60; Rheumatoid arthritis; Treg

Indexed keywords

APL 1; AUTOANTIGEN; COLLAGEN; INTERLEUKIN 10; INTERLEUKIN 17; METHOTREXATE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; HEAT SHOCK PROTEIN; IMMUNOLOGIC FACTOR; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; THERAPY EFFECT; ANIMAL; BLOOD; DBA MOUSE; DISEASE MODEL; EXPERIMENTAL ARTHRITIS; FLOW CYTOMETRY; IMMUNOLOGY; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANIMALS; ARTHRITIS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEAT-SHOCK PROTEINS; IMMUNOLOGIC FACTORS; INTERLEUKIN-10; MALE; METHOTREXATE; MICE, INBRED DBA; PEPTIDES; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84966545421     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-016-0412-7     Document Type: Article

References (45)

1. Prattm AG, Isaacs JD, Mattey DL. Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2009;23:37–48.
2. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology. 2004;43(7):906–14.
3. Kinder AJ, Hassell AB, Brand J, et al. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology. 2005;44(1):61–6.
4. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art. Nat Rev Rheumatol. 2009;5(10):531–41.
5. Castro-Rueda H, Kavanaugh A. Biologic therapy for early rheumatoid arthritis: the latest evidence. Curr Opin Rheumatol. 2008;3:314–9.
6. Van Vollenhoven RF, Klareskog L. Clinical responses to tumor necrosis factor α antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor α follow up registry. Arthritis Rheum. 2003;48:1500–3.
7. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology. 2012;51:38–47.
8. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.
9. Chatenoud L. Immune therapies of autoimmune diseases: Are we approaching a real cure? Curr Opin Immunol. 2006;18(6):710–7.
10. Myew-Ling T, Pierre M. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol. 2007;19:284–8.
11. Liston A, Gray D. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol. 2014;14:154–65.
12. Lourenço EV, La Cava A. Natural regulatory T cells in autoimmunity. Autoimmunity. 2011;44(1):33–42.
13. van Amelsfort J, Jacobs KMG, Bijlsma JWJ, et al. CD4 + CD25 + regulatory T cells in rheumatoid arthritis. Differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthitis Rheum. 2004;50(9):2775–85.
14. Nie H, Zheng Y, Li R, et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat Med. 2013;19:322–8.
15. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med. 2004;200(3):277–85.
16. Pasare C, Medzhitov R. Toll pathway dependent blockade of CD4 + CD25 + T cell-mediated suppression by dendritic cells. Science. 2003;299(5609):1033–6.
17. Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of human CD4 + CD25hi T-regulatory cells. Blood. 2006;108(1):253–61.
18. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–8.
19. Aruna BV, Sela M, Mozes E. Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4 + CD25 + regulatory cells. PNAS. 2005;102:10285–90.
20. Zhao J, Li R, He J, Shi J, et al. Mucosal administration of an altered CII263-272 peptide inhibits collagen-induced arthritis by suppression of Th1/Th17 cells and expansion of regulatory T cells. Rheumatol Int. 2008;29:9–16.
21. Katsara M, Deraos G, Tselios T, Matsoukas J, Apostolopoulos V. Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 That modulate immune responses in SJL/J Mice. J Med Chem. 2008;51:3971–8.
22. De Magistris M. Antigen analog-major complex histocompatibility complexes act as antagonist of the T cell receptor. Cell. 1992;68:625–34.
23. Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell ligand. Science. 1991;252:1308–10.
24. Paas-Rozner M, Sela M, Mozes E. A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating. PANAS. 2003;100:6676–81.
25. van Eden W, van der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol. 2005;5:318–30.
26. Zonneveld-Huijssoon E, Albani S, Prakken BJ, et al. Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease. Clin Exp Immunol. 2013;171(1):20–9.
27. Singh H, Raghava GPS. ProPred: prediction of HLA-DR binding sites. Bioinformatics. 2001;17:1236–7.
28. Domínguez MC, Lorenzo N, Barberá A, et al. An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant induced arthritis. Autoimmunity. 2011;44(6):471–82.
29. Barberá A, Lorenzo N, Garrido G, et al. APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4 + CD25 + T cells from peripheral blood of rheumatoid arthritis patients. Int Immunopharmacol. 2013;17(4):1075–83.
30. Alberta Paul GA, van Kooten PJS, van Eden W, et al. Highly autoproliferative T cells specific for 60-kDa heat shock protein produce IL-4/IL-10 and IFN-g and are protective in adjuvant arthritis. J Immunol. 2000;165:7270–7.
31. Luross JA, Williams NA. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology. 2001;103:407–16.
32. Garrood T, Pitzalis C. Targeting the inflamed synovium: the quest for specificity. Arthritis Rheum. 2006;54:1055–60.
33. Van Eden W, Van der Zee AGA, Prakken B, et al. Do heat shock proteins control the balance of T cell regulation in inflammatory diseases? Immunol Today. 1998;19:303–7.
34. Alberta P, van Kooten Peter JS, et al. Highly Autoproliferative T cells specific for 60-kDa heat shock protein produce IL-4/IL-10 and IFN γ and are protective in adjuvant arthritis. J Immunol. 2000;165:7270–7.
35. Yao ZQ, Li R, Li ZG. A triple altered collagen II peptide with consecutive substitutions of TCR contacting residues inhibits collagen-induced arthritis. Ann Rheum Dis. 2007;2007(66):423–4.
36. Reche PA, Glutting JP, Zhang H, et al. Enhancement to the RANKPEP resource for the prediction of peptide biding to MHC molecules using profiles. Immnigenetics. 2004;56:405–19.
37. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133–41.
38. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-Deficient Mice. J Immunol. 2003;171:6173–7.
39. Roncarolo MG, Battaglia M, Gregori S. The role of interleukin 10 in the control of autoimmunity. J Autoimmun. 2004;20(4):269–72.
40. Domínguez MC, Lorenzo N, Barberá A, et al. Therapeutic effect of two altered peptide ligands derived from the human heat shock protein 60 in experimental models of rheumatoid arthritis. Biotecnología Aplicada. 2013;30:153–6.
41. Scott DL, Kingsley GH. Tumor necrosis factors inhibitors for rheumatoid arthritis. N Engl J M. 2006;355:704–12.
42. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:904–16.
43. Carpentier I, Coormaert B, Beyaert R. Function and regulation of tumor necrosis factor type 2. Curr Med Chem. 2004;11:2205–12.
44. Neurath MF, Hilder K, Becker C, et al. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol. 1999;115:42–55.
45. Montesinos MC, et al. The anti-inflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5′-nucleotidase: findings in a study of ecto-5′-nucleotidase gene-deficient mice. Arthritis Rheum. 2007;56:1440–5.